The latest price target for Eton Pharmaceuticals (NASDAQ:ETON) was reported by B. Riley Securities on March 20, 2026. The analyst firm set a price target for $31.00 expecting ETON to rise to within 12 months (a possible 17.38% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Eton Pharmaceuticals (NASDAQ:ETON) was provided by B. Riley Securities, and Eton Pharmaceuticals maintained their buy rating.

There is no last upgrade for Eton Pharmaceuticals

There is no last downgrade for Eton Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eton Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eton Pharmaceuticals was filed on March 20, 2026 so you should expect the next rating to be made available sometime around March 20, 2027.

While ratings are subjective and will change, the latest Eton Pharmaceuticals (ETON) rating was a maintained with a price target of $26.00 to $31.00. The current price Eton Pharmaceuticals (ETON) is trading at is $26.41, which is within the analyst’s predicted range.